Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
50
PSTV Quote, Financials, Valuation and Earnings
Last price:
$0.59
Seasonality move
:
3.45%
Day range:
$0.56 - $0.61
52-week range:
$0.16 - $2.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.74x
P/B ratio:
16.53x
Volume:
3.8M
Avg. volume:
4.5M
1-year change:
-50.98%
Market cap:
$83.5M
Revenue:
$5.8M
EPS (TTM):
-$1.90
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PSTV
Plus Therapeutics, Inc.
|
$1.4M | -$0.04 | -1.06% | -93.96% | $7.16 |
|
CATX
Perspective Therapeutics, Inc.
|
$231.1K | -$0.35 | -9.65% | -37.91% | $12.3077 |
|
INFU
InfuSystem Holdings, Inc.
|
$36.7M | $0.05 | 8.36% | 39.86% | $14.20 |
|
VNRX
VolitionRX Ltd.
|
$714.1K | -$0.04 | 272.5% | -33.67% | $2.20 |
|
VTAK
Catheter Precision, Inc.
|
$310K | -$0.20 | 118.75% | -11.57% | -- |
|
XTNT
Xtant Medical Holdings, Inc.
|
$30.8M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PSTV
Plus Therapeutics, Inc.
|
$0.61 | $7.16 | $83.5M | -- | $0.00 | 0% | 9.74x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8700 | $12.3077 | $213.4M | -- | $0.00 | 0% | 194.60x |
|
INFU
InfuSystem Holdings, Inc.
|
$8.91 | $14.20 | $181.2M | 34.07x | $0.00 | 0% | 1.34x |
|
VNRX
VolitionRX Ltd.
|
$0.29 | $2.20 | $35.1M | -- | $0.00 | 0% | 19.58x |
|
VTAK
Catheter Precision, Inc.
|
$2.00 | -- | $2.5M | 0.40x | $0.00 | 0% | 9.40x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.72 | $1.50 | $100.8M | 70.59x | $0.00 | 0% | 0.79x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.184 | 0.02% | 1.22x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.042 | 11.73% | 1.35x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.723 | 15.4% | 0.04x |
|
VTAK
Catheter Precision, Inc.
|
68.63% | 0.156 | 537.37% | 0.41x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 3.120 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
VTAK
Catheter Precision, Inc.
|
-$320K | -$3M | -79.27% | -192.05% | -1336.73% | -$2.2M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
Plus Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns PSTV or CATX?
Perspective Therapeutics, Inc. has a net margin of -316.61% compared to Plus Therapeutics, Inc.'s net margin of -12425.36%. Plus Therapeutics, Inc.'s return on equity of -- beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About PSTV or CATX?
Plus Therapeutics, Inc. has a consensus price target of $7.16, signalling upside risk potential of 1077.61%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 328.84%. Given that Plus Therapeutics, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Perspective Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PSTVPlus Therapeutics, Inc.3 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is PSTV or CATX More Risky?
Plus Therapeutics, Inc. has a beta of 0.845, which suggesting that the stock is 15.456% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock PSTV or CATX?
Plus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PSTV or CATX?
Plus Therapeutics, Inc. quarterly revenues are $1.4M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Plus Therapeutics, Inc.'s net income of -$4.4M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Plus Therapeutics, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics, Inc. is 9.74x versus 194.60x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PSTVPlus Therapeutics, Inc.9.74x -- $1.4M -$4.4M CATXPerspective Therapeutics, Inc.194.60x -- $209K -$26M
-
Which has Higher Returns PSTV or INFU?
InfuSystem Holdings, Inc. has a net margin of -316.61% compared to Plus Therapeutics, Inc.'s net margin of 6.19%. Plus Therapeutics, Inc.'s return on equity of -- beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.
Company Gross Margin Earnings Per Share Invested Capital PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M -
What do Analysts Say About PSTV or INFU?
Plus Therapeutics, Inc. has a consensus price target of $7.16, signalling upside risk potential of 1077.61%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 59.37%. Given that Plus Therapeutics, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PSTVPlus Therapeutics, Inc.3 0 0 INFUInfuSystem Holdings, Inc.5 0 0 -
Is PSTV or INFU More Risky?
Plus Therapeutics, Inc. has a beta of 0.845, which suggesting that the stock is 15.456% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.
-
Which is a Better Dividend Stock PSTV or INFU?
Plus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PSTV or INFU?
Plus Therapeutics, Inc. quarterly revenues are $1.4M, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Plus Therapeutics, Inc.'s net income of -$4.4M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Plus Therapeutics, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 34.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics, Inc. is 9.74x versus 1.34x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PSTVPlus Therapeutics, Inc.9.74x -- $1.4M -$4.4M INFUInfuSystem Holdings, Inc.1.34x 34.07x $36.5M $2.3M
-
Which has Higher Returns PSTV or VNRX?
VolitionRX Ltd. has a net margin of -316.61% compared to Plus Therapeutics, Inc.'s net margin of -862.39%. Plus Therapeutics, Inc.'s return on equity of -- beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About PSTV or VNRX?
Plus Therapeutics, Inc. has a consensus price target of $7.16, signalling upside risk potential of 1077.61%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 670.04%. Given that Plus Therapeutics, Inc. has higher upside potential than VolitionRX Ltd., analysts believe Plus Therapeutics, Inc. is more attractive than VolitionRX Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PSTVPlus Therapeutics, Inc.3 0 0 VNRXVolitionRX Ltd.4 2 0 -
Is PSTV or VNRX More Risky?
Plus Therapeutics, Inc. has a beta of 0.845, which suggesting that the stock is 15.456% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.
-
Which is a Better Dividend Stock PSTV or VNRX?
Plus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PSTV or VNRX?
Plus Therapeutics, Inc. quarterly revenues are $1.4M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Plus Therapeutics, Inc.'s net income of -$4.4M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Plus Therapeutics, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics, Inc. is 9.74x versus 19.58x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PSTVPlus Therapeutics, Inc.9.74x -- $1.4M -$4.4M VNRXVolitionRX Ltd.19.58x -- $627.3K -$5.4M
-
Which has Higher Returns PSTV or VTAK?
Catheter Precision, Inc. has a net margin of -316.61% compared to Plus Therapeutics, Inc.'s net margin of -1037.17%. Plus Therapeutics, Inc.'s return on equity of -- beat Catheter Precision, Inc.'s return on equity of -192.05%.
Company Gross Margin Earnings Per Share Invested Capital PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M -
What do Analysts Say About PSTV or VTAK?
Plus Therapeutics, Inc. has a consensus price target of $7.16, signalling upside risk potential of 1077.61%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1800.06%. Given that Catheter Precision, Inc. has higher upside potential than Plus Therapeutics, Inc., analysts believe Catheter Precision, Inc. is more attractive than Plus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PSTVPlus Therapeutics, Inc.3 0 0 VTAKCatheter Precision, Inc.0 0 0 -
Is PSTV or VTAK More Risky?
Plus Therapeutics, Inc. has a beta of 0.845, which suggesting that the stock is 15.456% less volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.392, suggesting its less volatile than the S&P 500 by 239.195%.
-
Which is a Better Dividend Stock PSTV or VTAK?
Plus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PSTV or VTAK?
Plus Therapeutics, Inc. quarterly revenues are $1.4M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. Plus Therapeutics, Inc.'s net income of -$4.4M is lower than Catheter Precision, Inc.'s net income of -$2.3M. Notably, Plus Therapeutics, Inc.'s price-to-earnings ratio is -- while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics, Inc. is 9.74x versus 9.40x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PSTVPlus Therapeutics, Inc.9.74x -- $1.4M -$4.4M VTAKCatheter Precision, Inc.9.40x 0.40x $226K -$2.3M
-
Which has Higher Returns PSTV or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -316.61% compared to Plus Therapeutics, Inc.'s net margin of 3.93%. Plus Therapeutics, Inc.'s return on equity of -- beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About PSTV or XTNT?
Plus Therapeutics, Inc. has a consensus price target of $7.16, signalling upside risk potential of 1077.61%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 108.33%. Given that Plus Therapeutics, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Xtant Medical Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PSTVPlus Therapeutics, Inc.3 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is PSTV or XTNT More Risky?
Plus Therapeutics, Inc. has a beta of 0.845, which suggesting that the stock is 15.456% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.
-
Which is a Better Dividend Stock PSTV or XTNT?
Plus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PSTV or XTNT?
Plus Therapeutics, Inc. quarterly revenues are $1.4M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Plus Therapeutics, Inc.'s net income of -$4.4M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Plus Therapeutics, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 70.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics, Inc. is 9.74x versus 0.79x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PSTVPlus Therapeutics, Inc.9.74x -- $1.4M -$4.4M XTNTXtant Medical Holdings, Inc.0.79x 70.59x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
70
RGC alert for Jan 8
Regencell Bioscience Holdings Ltd. [RGC] is down 21.5% over the past day.
Buy
64
RVMD alert for Jan 8
Revolution Medicines, Inc. [RVMD] is up 4.61% over the past day.
Sell
38
CRNX alert for Jan 8
Crinetics Pharmaceuticals, Inc. [CRNX] is down 0.23% over the past day.
